Page 5 - Sight Biologic News Today

Press release content from Business Wire. The AP news staff was not involved in its creation. GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye May 3, 2021 GMT Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire) Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire) PARIS--(BUSINESS WIRE)--May 3, 2021-- Regulatory News:...

GenSight Biologics Announces the Filing of its 2020 Universal Registration Document Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2020 Universal Registration Document (URD) in English with the French market authority ( Autorités des March...

GenSight Biologics: Annual General Meeting on April 29, 2021 Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting behind closed doors (without the presence of shareholders) on April 29, 2021 at 9:00 am CET at the Companys hea...

Press release content from Business Wire. The AP news staff was not involved in its creation. GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/IIa Clinical Trial REVEAL in BioDrugs February 15, 2021 GMT Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders...

Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the journal BioDrugs has published results from REVEAL, the Phase I/IIa clinical trial that evaluated the safety of LUMEVOQ ® gene therapy in subjects with ND4 Leber Hereditary Optic Neuropathy (LHON) an...

GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non-Human Primates The ex vivo retinal stimulation assays also showed that the electrophysiologic response of RGCs expressing ChrimsonR precisely followed the duration and frequency of the light pulses used to activate the opsin. Moreover, localized stimulation of RGCs induced a response coherent with the size and position of the light pulses. Optogenetic stimulation of RGCs...

GenSight Biologics Announces its 2021 Financial Calendar Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calendar for 2021. Information March 10, 2021 July 29, 2021 January 18, 2022 * This financial calendar is provided for information only and ...

Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the journal of the American Academy of Ophthalmology, Ophthalmology ® gene therapy in ND4 Leber Hereditary Optic Neuropathy (LHON) subjects. The paper*, published in the January issue under the title, �...

GenSight Biologics Announces Publication of Results from LUMEVOQ REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine Non-human primate study clarifies mechanism behind contralateral effect Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorde...

GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital Company" or " GenSight"), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announces today that it has received, in connection with its bond agreement entered with Kreos Capital VI (Expert Fund) LP (" Kreos"), the notification by Kreos of (i) the conversion...